When to consider continuous subcutaneous insulin infusion (CSII)

1987 ◽  
Vol 25 (7) ◽  
pp. 25-28

Most physicians agree that the aim of diabetic management is to achieve the best possible blood glucose control without troublesome hypoglycaemia. Continuous subcutaneous infusion of insulin (CSII) via a battery-operated portable pump was introduced in 1977 with this aim, originally as a research technique to study the effects of prolonged near-physiological blood glucose levels in diabetic patients.1 It provides a continuous basal supply of unmodified, short-acting insulin throughout 24 hours with supplementary boluses before main meals, activated by the user from the same pump. Its introduction coincided with the move towards intensified conventional therapy (ICT) together with better education: improved blood-sugar control with self-monitoring of capillary blood glucose, more frequent insulin injections when necessary, and measurement of glycosylated haemoglobin (an index of average blood glucose control over the preceding month). The aim of ICT is to maintain a continuous basal supply of insulin using a long-acting insulin with bolus injections of short-acting insulin to cover meals.

Diabetes Care ◽  
1996 ◽  
Vol 19 (9) ◽  
pp. 945-952 ◽  
Author(s):  
E. Torlone ◽  
S. Pampanelli ◽  
C. Lalli ◽  
P. D. Sindaco ◽  
A. D. Vincenzo ◽  
...  

1981 ◽  
Author(s):  
Ph Voisin ◽  
D Rouselle ◽  
C Guimont ◽  
P Drouin ◽  
J F Stoltz

Plasma β-thromboglobulin was measured at 0, 24 and 48 hours on 27 healthy subjects and 22 insulin-dependent diabetic patients undergoing a 48-hour artificial pancreas treatment (Biostator).Before treatment all the diabetic patients revealed β-TG levels which were significantly higher than those measured in healthy subjectsOn average, after 24 hours of blood glucose control, β-TG levels in the diabetic patients were not significantly reduced in comparison with the original β-TG levels. In contrast, after 48 hours of blood glucose control, plasma β-TG levels were significantly reduced.As β-TG is a platelet-specific protein, which is considered to be an indicator of the cell’s release reaction, these results suggest that short-term control of blood glucose levels is likely to influence platelet activation in diabetic patients.


2004 ◽  
Vol 7 (2) ◽  
pp. 4-8 ◽  
Author(s):  
PAUL S JELLINGER

The basis of strict glucose control and the achievement of a favorable HgbAlc must involve the control of both fasting and post-prandial glucose levels. Most of the day is spent in the post-prandial state. The most important predictor of post prandial glycemia is the pre-prandial glucose. Glucose control in the United States is far from optimal with a minority of patients achieving either the ADA goal of 7.0% or the ACE/AACE goal of 6.5%. There is evidence that post-meal glucose has a better correlation with A1C than fasting glucose levels especially when the A1C is less than 8%. A reduced early insulin release leads to high postprandial glucose. The evidence that lowering Hgb A1C results in lower microvascular risk is substantial. The DCC T demonstrated a clear association, of retinopathy with A1C . The study also demonstrated that for the same Al C, intensive glucose control using short-acting insulin pre-meals was associated with reduced complications compared to conventional treatment without short acting insulin. Further evidence from the Kumamoto Study and the UKPDS confirm reduced microvascular complications with lower A1C levels. Elevated mealtime glucose is an unappreciated concern at all levels of A1C including A1C levels at normal or near normal values. Elevated mealtime glucose is of special concern in the elderly. There is strong epidemiologic evidence linking post challenge hyperglycemia to macro-vascular risk. These include the Rancho Bernardo study the Honolulu Heart Study, the Paris Prospective Heart Study, The Diabetes Intervention Study, and the DECODE Study. There are many other studies going back to the 1980s that relate post-challenge or post-prandial blood glucose to cardiovascular disease risk and mortality. Possible effects of acute hyperglycemia responsible for increased microvascular and macrovascular risk include endothelial dysfunction, increased oxidative load, a pro-inflammatory state, protein glycosylation and altered coagulation. There is evidence that oral glucose loading adversely affects endothelial function. Oxidative load in the form of reactive oxygen species is increased following a glucose challenge. The pro-inflammatory state relates to quintiles of dietary glycemic load as it does to the 2- hour post challenge glucose category. There is evidence that in intimal media thickness increases more with the 2 hour glucose than A 1С. In summary, post mealtime glucose spikes are to be prevented because lowering A1C reduces microvascular complications, A1C reflects post mealtime glucose as well as fasting plasma group glucose, elevated post-meal glucose is a highly prevalent issue and elevated blood glucose 2 hours after a glucose load is associated with increased risk of death independent of fasting blood glucose. The Epic- Norfork study raises questions as to the level of A1C associated with risk.


2007 ◽  
Vol 23 (2) ◽  
pp. 184-189 ◽  
Author(s):  
Michael E. Matheny ◽  
Maria Shubina ◽  
Zebadiah M. Kimmel ◽  
Merri L. Pendergrass ◽  
Alexander Turchin

2013 ◽  
Vol 8 (2) ◽  
pp. 107-119 ◽  
Author(s):  
Katrin Lunze ◽  
Tarunraj Singh ◽  
Marian Walter ◽  
Mathias D. Brendel ◽  
Steffen Leonhardt

MedPharmRes ◽  
2021 ◽  
Vol 5 (2) ◽  
pp. 22-28
Author(s):  
Uyen Vy Doan ◽  
Thanh Thao T. Nguyen ◽  
Thuy An Nguyen ◽  
Van Hoang Lam ◽  
Duong Tien Truong ◽  
...  

Introduction: Herbal antidiabetic products are popular in Vietnam. Many cases have presented to hospitals with severe lactic acidosis, shock and were ultimately fatal. We reviewed the clinical findings of these patients for factors that contributed to their illness and death, and analyzed the ingredients contained in these herbal products sold for diabetic treatment. Method: This was a single-center, retrospective, observational case series. Data were collected on all cases who presented with severe lactic acidosis after use of traditional herbal anti-diabetic pills, over the two-year time period 2018 – 2019. Past medical histories and clinical findings were reviewed. Samples of the herbal anti-diabetic products, and patient blood and urine were analyzed. Results: A total of 18 cases of severe lactic acidosis associated with use of herbal anti-diabetic pills were reviewed. These patients had a diagnosis of diabetes for an average of 9 years (9.4 ± 4.6 years). The use of these herbals for blood glucose control ranged from one month to 8 years; approximately 50% of these patients consumed these products over a year’s time. Only two cases had combined herbal products and metformin 500 mg. A total mean of herbal pills consumed was 9 (SD ± 8); patients commonly took combinations of 2 different colored tablets. Major manifestations included gastrointestinal disorders, severe metabolic acidosis (pH = 6.85 ± 0.22, HCO3- = 4.4 ± 2.6), with multi-organ failure and shock on admission. Hyperlactatemia was present in all cases (195 ± 74 mg/dL). For lactate removal and acidosis correction, intermittent hemodialysis or continuous renal replacement therapy was performed, ranging from 2 hours to 72 hours depending on the severity of lactic acidosis and patient need. The mortality rate was 33.3% and all these patients became hypoglycemic, either at initial presentation or during treatment. 22 samples of herbal pills were available for testing that contained the biguanides metformin and phenformin, with a higher concentration of phenformin than metformin if both were present, Phenformin was presented in all samples. Arsenic was found in two samples. Conclusion: Biguanides are an effective treatment for diabetes and were added to traditional herbal pills sold and used for blood glucose control. Many users of these products are doing so because of the cost and perception of the safety of natural remedies. Biguanide poisoning may still occur even in patients without renal impairment.


1966 ◽  
Vol 4 (13) ◽  
pp. 52-52

This article stated that Actrapid and Nuso insulins can be mixed with protamine zinc insulin and other long-acting insulins. This is true, but we should have made it clear that in such a mixture the time-action characteristics of its components are likely to be altered, for some of the short-acting insulin is probably bound by the long-acting one.


1985 ◽  
Vol 110 (4_Suppl) ◽  
pp. S57-S60 ◽  
Author(s):  
Kristian F. Hanssen ◽  
Knut Dahl-Jørgensen ◽  
Olaf Brinchmann-Hansen ◽  
_ _

Abstract. We studied 45 IDDM without c-peptide response, duration 7-22 years, without proliferative retinopathy. After 2 months run-in period, they were randomly assigned to: (P) 15 received CSII: (C) 15 received muliple s.c. injections via butterfly 5-6x daily;: (M) 15 received twice daily mixed rapid and long acting insulin. All groups improved blood glucose control in the run-in period (p<0.0001). After change of treatment (P) and (M) improved further (p<0.01) but (C) was unchanged. GFR was supranormal and decreased in (P) and (M). No regression of retinopathy was shown in any group. One in (P) had transient florid pre-proliferative retinopathy which regressed spontaneously without laser treatment. We conclude that retinal response to strict control is complex. A transient deterioration may been seen.


1999 ◽  
Vol 16 (4) ◽  
pp. 319-324 ◽  
Author(s):  
A. Colombel ◽  
A. Murat ◽  
M. Krempf ◽  
B. Kuchly-Anton ◽  
B. Charbonnel

Sign in / Sign up

Export Citation Format

Share Document